151 related articles for article (PubMed ID: 36096359)
1. Generic dry powder inhalers bioequivalence: Batch-to-batch variability insights.
Salama R; Choi HJ; Almazi J; Traini D; Young P
Drug Discov Today; 2022 Nov; 27(11):103350. PubMed ID: 36096359
[TBL] [Abstract][Full Text] [Related]
2. Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development.
Mohan AR; Wang Q; Dhapare S; Bielski E; Kaviratna A; Han L; Boc S; Newman B
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432683
[TBL] [Abstract][Full Text] [Related]
3. Scientific and regulatory activities initiated by the U.S. Food and drug administration to foster approvals of generic dry powder inhalers: Bioequivalence perspective.
Newman B; Babiskin A; Bielski E; Boc S; Dhapare S; Fang L; Feibus K; Kaviratna A; Li BV; Luke MC; Ma T; Spagnola M; Walenga RL; Wang Z; Zhao L; El-Gendy N; Bertha CM; Abd El-Shafy M; Gaglani DK
Adv Drug Deliv Rev; 2022 Nov; 190():114526. PubMed ID: 36067967
[TBL] [Abstract][Full Text] [Related]
4. Batch-to-batch pharmacokinetic variability confounds current bioequivalence regulations: A dry powder inhaler randomized clinical trial.
Burmeister Getz E; Carroll KJ; Jones B; Benet LZ
Clin Pharmacol Ther; 2016 Sep; 100(3):223-31. PubMed ID: 27037630
[TBL] [Abstract][Full Text] [Related]
5. Effect of Device Design and Formulation on the In Vitro Comparability for Multi-Unit Dose Dry Powder Inhalers.
Shur J; Saluja B; Lee S; Tibbatts J; Price R
AAPS J; 2015 Sep; 17(5):1105-16. PubMed ID: 25956383
[TBL] [Abstract][Full Text] [Related]
6. Drilling down the bioequivalence assessment of topical antifungal products: Microstructure and release.
Miranda M; Cardoso C; Pais AACC; Brown M; Vitorino C
Eur J Pharm Biopharm; 2023 Apr; 185():94-106. PubMed ID: 36806630
[TBL] [Abstract][Full Text] [Related]
7. Batch Selection via In Vitro/In Vivo Correlation in Pharmacokinetic Bioequivalence Testing.
Burmeister Getz E; Carroll KJ; Mielke J; Jones B; Benet LZ
AAPS PharmSciTech; 2021 Aug; 22(7):224. PubMed ID: 34410534
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence assessment of pharmaceutical aerosol products through IVIVC.
Sandell D
Adv Drug Deliv Rev; 2021 Sep; 176():113895. PubMed ID: 34329687
[TBL] [Abstract][Full Text] [Related]
9. Understanding the Essentialities in Establishing the Bioequivalence of Oral Inhalation Drug Products to be Marketed in the USA.
Fernandes SD; Koland M
Ther Innov Regul Sci; 2020 Jul; 54(4):738-748. PubMed ID: 32557296
[TBL] [Abstract][Full Text] [Related]
10. Performance of the Population Bioequivalence (PBE) Statistical Test with Impactor Sized Mass Data.
Chen S; Morgan B; Beresford H; Burmeister Getz E; Christopher D; Långström G; Strickland H; Wiggenhorn C; Lyapustina S
AAPS PharmSciTech; 2019 Aug; 20(7):296. PubMed ID: 31444601
[TBL] [Abstract][Full Text] [Related]
11. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
Muralidharan P; Hayes D; Mansour HM
Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
[TBL] [Abstract][Full Text] [Related]
12. Performance of Multiple-Batch Approaches to Pharmacokinetic Bioequivalence Testing for Orally Inhaled Drug Products with Batch-to-Batch Variability.
Burmeister Getz E; Carroll KJ; Christopher JD; Morgan B; Haughie S; Cavecchi A; Wiggenhorn C; Beresford H; Strickland H; Lyapustina S
AAPS PharmSciTech; 2021 Aug; 22(7):225. PubMed ID: 34410557
[TBL] [Abstract][Full Text] [Related]
13. Combined in Vitro-in Silico Approach to Predict Deposition and Pharmacokinetics of Budesonide Dry Powder Inhalers.
Ruzycki CA; Murphy B; Nathoo H; Finlay WH; Martin AR
Pharm Res; 2020 Sep; 37(10):209. PubMed ID: 32995953
[TBL] [Abstract][Full Text] [Related]
14. Evaluating dry powder inhalers: From in vitro studies to mobile health technologies.
Ari A; Alhamad BR
Respir Med; 2023; 215():107281. PubMed ID: 37244487
[TBL] [Abstract][Full Text] [Related]
15. Dry powder inhalers (DPIs)--a review of device reliability and innovation.
Islam N; Gladki E
Int J Pharm; 2008 Aug; 360(1-2):1-11. PubMed ID: 18583072
[TBL] [Abstract][Full Text] [Related]
16. Diving into Batch-to-Batch Variability of Topical Products-a Regulatory Bottleneck.
Miranda M; Cova T; Augusto C; Pais AACC; Cardoso C; Vitorino C
Pharm Res; 2020 Oct; 37(11):218. PubMed ID: 33037479
[TBL] [Abstract][Full Text] [Related]
17. In vitro tests for aerosol deposition II: IVIVCs for different dry powder inhalers in normal adults.
Delvadia R; Hindle M; Longest PW; Byron PR
J Aerosol Med Pulm Drug Deliv; 2013 Jun; 26(3):138-44. PubMed ID: 22947131
[TBL] [Abstract][Full Text] [Related]
18. Raw material variability of an active pharmaceutical ingredient and its relevance for processability in secondary continuous pharmaceutical manufacturing.
Stauffer F; Vanhoorne V; Pilcer G; Chavez PF; Rome S; Schubert MA; Aerts L; De Beer T
Eur J Pharm Biopharm; 2018 Jun; 127():92-103. PubMed ID: 29452241
[TBL] [Abstract][Full Text] [Related]
19. An overview of regulations for bioequivalence assessment of locally acting orally inhaled drug products for the United States, Europe, Canada, and India.
Patil PP; Pawar AP; Mahadik KR; Gaikwad VL
Expert Opin Drug Deliv; 2021 Dec; 18(12):1843-1855. PubMed ID: 34814778
[TBL] [Abstract][Full Text] [Related]
20. Batch-to-Batch and Within-Subject Variability: What Do We Know and How Do These Variabilities Affect Clinical Pharmacology and Bioequivalence?
Benet LZ; Jayachandran P; Carroll KJ; Burmeister Getz E
Clin Pharmacol Ther; 2019 Feb; 105(2):326-328. PubMed ID: 30652313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
